Floatz logo

bhb810

CDH17-positive Advanced Solid Tumors

BigHat Biosciences, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CDH17-positive Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Anti-Cdh17 Car-T Cells
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Early Phase 1C

Same molecule, other indications

bhb810 is also rated in:

digestive system cancerDormant
CCC
Indicative ·
48 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →